HUMANTIN *
Manufacturer Details
PARKE-DAVIS INC
Compositions:
Paromomycin sulfate 250mg caps,
|
Strength
|
Rate
|
Packing Style
|
|
250mg
|
0.00
|
Tab
|
List of Related Indications:
List Of Drugs:
- Paromomycin- @- Aminoglycoside Oral- Amebicides- (Aug 2006)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Since paromomycin is an aminoglycoside, consider the interactions that may occur with other oral aminoglycosides as potentially occuring with paromomycin as well
Indication:
LIST OF DRUGS DURING 2006
Sr.No- 134
Name of the Drug- Paromomycin inj 375mg/ml Pharmacological Classification- For visceral leishmaniasis (Kalazar)
Date of Approval- 30-08-2006
Approved by U.S.FDA on 30-12-2006 (Ref- FDA approved List)
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Paromomycin Inj 30.08-2006
375mg/ml
For Visceral Leishmaniasis (Kala Azar)
Acute and chronic intestinal amebiasis
Adverse Reaction:
Nausea, abdominal cramps and diarrhea.
Contra-Indications:
Hypersen to the drug Special precautions: Ototoxicity and renal damage
Dosages/ Overdosage Etc:
Indications: Acute and chronic intestinal amebiasis
Dosage: Adults and children- 25 to 35mg/kg/day in 3 divided doses with meals for 5 to 10 days.
Patient Information:
1. Complete full course of theapy
2. May cause nausea, vomiting, or diarrhea.
3. Notify physician if ringing in the eares or impairment or dizziness occurs.
Pharmacology/ Pharmacokinetics:
Pharmacology: Paromomycin is an amebicidal and antibacterial aminoglycoside obtained from the strains of Streptomyces rimosus and is active in intestinal amoebiasis.
Interaction with Food:
To be taken given with meals
